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1.1 Introduction 
 
The World Health Organization reports that in 2008 cardiovascular diseases 
(CVDs) were the leading cause of death, with 17 million deaths and an estimated 
23.6 million people will die from CVDs each year by 2030 (www.who.int, 2008) 
(Figure 1). Cardiovascular-related disorders account for the highest mortality 
rates in the world, and affect the quality and the quantity of life of patients, 
creating an economic burden of prolonged therapeutic intervention. (White MY 
et al., 2007)  For these reasons there is a great interest in understanding and 
study the CVDs from different points of view, trying to uncover the cellular and 
the molecular alterations that influence the progressions of these pathologies, to 
improve the diagnostic tools and to optimized the therapeutic interventions. 
Myxomatous valve disease (MVD) is the most common heart valvular disease in 
humans in Europe and United States, and it’s the primary naturally occurring 
heart disease in dogs(Lacerda et al., 2009). MVD is pathologically identical in 
humans and dogs, suggesting a common pathogenesis in these species, and 
creating an increasing interest in the canine MVD as a model for the human 
medicine. Nowadays, MVD is one of the most studied CVDs, because of its 
high prevalence in the clinical practice. In veterinary medicine the prevalence, 
especially in old, small breed dogs, approaches 100%, thus the incidence of 
MVD over canine lifetimes in most breeds is close to 100%. Thanks to the 
research efforts, great diagnostic and therapeutic progresses have been made in 
the last decades, and continuous improvement are in the making. The diagnostic 
tools required for MVD assessment are actually large scale used, both in human 
and in veterinary medicine, allowing an effective clinical management. The 
therapeutic intervention are day by day more precise, and in human medicine the 
surgical intervention on the mitral valve is a common practice. In recent years, 
new technologies have been used by the cardiovascular medicine, and the 
advancement of proteomic techniques has improved the methods available for 
investigating CVDs.(Cui Z. et al., 2011). Proteomics is the large-scale study of 
proteins and its application to uncover the protein function and structure in 
normal or disease states in the cardiovascular field is called cardiovascular 
proteomics. (Cui Z. et al., 2011) Through the cardiovascular proteomics the 
clinician could get important data that can be matched with the classical clinical 
and diagnostic features, in order to ensure a faster or more precise diagnosis, or 
a better management of the cardiovascular patient. Even if the use of 
cardiovascular biomarkers is widespread in both human and veterinary medicine, 
the application of cardiovascular proteomics to the MVD study has recently 
begun.  
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Figure 1 Interactive graph: CVDs and diabetes deaths in 2008. (WHO website) 
In the present study we selected a cohort of private-owned dogs recruited from 
the Cardiologic Service of the Department of Veterinary Science and Public 
Health. The dogs were selected with precise inclusion and exclusion criteria. 
Two breeds were considered: Cirneco dell’Etna and Cavalier King Charles 
Spaniels. The Cirneco dell’Etna breed is a poorly diffuse Italian hunting breed 
whose CVDs prevalence has never been studied before, while the Cavalier King 
Charles Spaniel breed is the most studied breed for all the MVD researches, 
because of the high prevalence of MVD, the early onset and the strong 
scientifically proved hereditary component. The objective of the present study 
was to search one or more than one serological biomarkers in dogs affected by 
MVD, comparing blood samples from the healthy dogs of the groups with blood 
samples from the dogs affected by different stages of MVD.  The proteomics 
results were then matched with the clinical and echocardiographic data obtained 
in the clinical trial of all the patients included in the study, to find a connection 
available in the clinical practice. 
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2.1 Mitral Valve Disease (MVD) 
 
Mitral valve disease is the most common acquired cardiovascular disease in dogs 
and the most frequent valvular heart disease of humans in the richest countries 
(Europe and United States). In the dog MVD represents the 75% of all CVDs, 
affecting primary the mitral valve, while in the 30% of the affected dogs both 
mitral and tricuspid valves are involved. (Atkins et al., 2009; Borgarelli & 
Haggstrogm, 2010). Various other names for the disease include endokarditis 
valvularis chronica fibrosa (nodosa), chronic valvular endocarditis, chronic 
valvular disease, billowing sail distortion of the mitral valve, endocardiosis, 
chronic mitral valve fibrosis, senile nodular sclerosis, mucoid degeneration,  
chronic myxomatous valve disease, and degenerative mitral valve disease. 
Chronic MVD  in dogs has been known to cause congestive heart failure (CHF) 
in dogs for more than 100 years. (Borgarelli & Buchanan, 2012) 
2.2 Etiology and prevalence  
 
The prevalence of MVD varies with age and whether the study is based on 
necropsy or clinical findings. Most frequency data are based on auscultation of a 
mitral insufficiency murmur. The disease is age related and the prevalence, 
especially in old, small breed dogs, approaches 100% thus the incidence of MVD 
over canine lifetimes in most breeds is close to 100%.  (Fig. 2) (Borgarelli & 
Buchanan, 2012) The vast majority of the breeds at elevated risk of MVD are 
small or toy breeds, and males are 1.5 times more represented than females.  In 
human medicine MVD is more prevalent in females than males, but equally to 
canine MVD, the prevalence of MVD in the human population is associated 
with age, and the patients with mitral valve prolapse tend to have low body mass 
index, but the reason for this phenomenon is uncertain. (Aupperle & Disatian,  
2012) In human medicine height has been linked to a variety of heart diseases. 
The first study in 1951. published by the Journal of American Medical 
Association, examined the physical characteristics 
of 100 humans that underwent a myocardial 
infarction, and found that they were 5 cm shorter 
than the control group. In 2010 a meta-analysis 
was conducted on a  combined dataset of  more 
than 3 million individuals. They showed that the 
risk of cardiovascular death in this combined 
group was  50% higher in short men and women 
than in tall men and women. (Parker & Kilroy-
Glynn, 2012) It is interesting to note that the 
correlation between dog size and canine MVD is 
Figure 2 Bar chart showing the percentage 
distribution of 4 grades of chronic valvular 
disease by age in 200 dogs. (Whitney, 1967) 
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similar to what human medicine discovered about height and cardiovascular 
diseases. The cause of canine MVD is currently unknown, although a genetic 
tendency to develop the disease has been proven. Some breeds such as the 
Cavalier King Charles Spaniel (CKCS) and the dachshund are particularly 
predisposed to the development of MVD, with a prevalence of the disease in 
CKCS older than 10 years of more than 90%. In this breed in particular, a 
polygenic mode of inheritance is suggested by a strong inherited component, and 
recently two loci have been associated with MVD in CKCS. (Parker & Kilroy-
Glynn, 2012; Madsen et al., 2011)  In addition poorly defined environmental 
factors play a role in the rate of onset or severity of the disease. MVD has been 
considered as a non-inflammatory myxomatous degeneration of the 
atrioventricular valves, but now a growing interest in the role that serotonin and 
other inflammatory mediators may play in the pathology is arising. (Rusch, 2009) 
The report of Rush et al. of 2006 (Rush et al., 2006) revealed a higher 
concentration of C-reactive protein in dogs affected by MVD, suggesting a 
possible role of systemic inflammation in the pathogenesis.  At the same way, 
the etiology of human MVD is unknown. The risk factor of mitral valve prolapse 
may be inherited as an autosomal dominant or a polygenic abnormality and it 
often displays familial transmission.  (Aupperle & Disatian,  2012) 
2.3 Histopathological findings 
 
The macroscopic appearance of MVD in dogs varies 
from small focal thickening in the contact zone, to large 
areas of smooth surfaced nodular thickening of the distal 
portion of all leaflets and commissural cusp tissue, 
depending on the stage of degeneration. In severe cases 
the thickening extends into proximal segments of the 
attached primary chordae tendineae. Lengthening and 
rupture of chordae tendineae are also common in dogs 
with advanced MVD. (Fig. 3) (Borgarelli & Buchanan, 
2012) In the 1974 Whitney presented a classification 
system of the atrioventricular lesions  that is still actual.  
 
The method divided the progression of MVD  into four 
types of lesions: 
 
Type I lesion 
A few small oedematous nodules are seen in the area of apposition, opposite to 
the origins of the chordae tendineae. The chordae tendineae themselves are 
unchanged. There is no valvular incompetence 
Figure 3 The 4 types of 
atrioventricular lesions 
presented by Whitney. 
(Whitney, 1974) 
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Type II lesion 
Here the oedematous nodules are larger and more numerous and some are 
greyish-white in colour. These lesions are confined to the area of apposition, the 
chordae tendineae are unaffected and there is no evidence of valvular 
incompetence 
 
Type III lesion 
Here there are larger greysh-white nodules and plaque-like elevations located in 
the area of apposition and associated with thickening and irregularity of the 
proximal portion of the chordae tendineae, where they join the inflow surface of 
the valve cusp. There is evidence of valvular incompetence in some of these 
cases 
 
Type IV lesion 
Here there are large greysh-white nodules and plaque-like elevations situated in 
the area of apposition and  an associated thickening and irregularity of related 
chordae tendineae. These chordae may be stretched and ruptured in some cases. 
There is evidence of valvuar incompetence in the majority of these cases. 
 
The microscopic features of normal canine and human mitral valves are three 
well-defined layers: the atrialis, the spongiosa and the fibrosa. The atrialis layer is 
mainly composed of elastic fibers, the spongiosa layer is rich in 
glycosaminoglycans and the fibrosa layer predominantly consists of densely-
packed collagen bundles. 
The microscopic aspect of myxomatous valves in humans and in dogs includes 
increased cellularity and disorganization as well as transdifferentiation of valve 
endothelial and valve interstitial cells. In canine degenerated valves, the changes 
occur primarily in the atrialis layer by an accumulation of transformed valve 
interstitial cells. In the advanced stages, the major structural changes, as 
glycosaminoglycan infiltration, appear in the spongiosa layer, both in human and 
canine MVD . The degeneration is most pronounced at the free margins of the 
leaflets. When the disease progresses, the amount of glycosaminoglycans 
increases and invades into the other layers. The elastic fibers become fragmented 
and split, the collagen bundles are disorientated by glycosaminoglycan 
infiltration, and the collagen fibrils also appear disrupted. Similar changes occur 
in the chordae tendineae. The anterior leaflet is more frequently involved in 
canine MVD, while the posterior leaflet is more often and more severely affected 
than the anterior leaflet in humans. (Aupperle & Disatian,  2012) 
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2.4 Natural history and physiopathology 
 
“The natural history of MVD in dogs is a story of aging, stress, functional effects 
and the development of complications. The mitral valve is probably the most 
abused and stressed tissue in the body because it is intermittently bent, slammed, 
tensed, shear stressed and stretched, 200 times a minute, 24 h a day, 365 days a 
year for 10-15 years. The wonder is not that it degenerates but rather how it 
survives so well.” (Borgarelli &Buchanan, 2012) This sentence has been 
published on an important article that review the natural history of mitral valve 
disease, and encloses the physiopathology of the disease. Chronic mitral valve 
disease has a long pre-clinical period characterized initially by morphologic 
changes observed only on necropsy in the first third of life. The progression to 
mitral valve insufficiency is observed mainly in the middle third, and it may lead 
to secondary chamber dilation and hypertrophy in the latter third of life.  
During the first stages of MVD the affected valves preserve their competence 
and no hemodynamic abnormalities are observed. When the morphologic 
alterations of the leaflets result in mitral regurgitation, the pressure of the left 
atrium increases, and the cardiac output decreases. Classic compensatory 
mechanisms (sympathetic nervous system activation, enhanced renin-angiotensin 
system activity) are activated in an attempt to restore blood pressure and tissue 
perfusion. 
The sympathetic system determines:  
- Venous vasoconstriction to increase venous return to the heart 
- Arterial vasoconstriction to preserve constant arterial blood pressure 
- Increase of heart rate and myocardial contractility to preserve cardiac 
output 
The Renin-Angiotensin system determines: 
- Vasoconstriction mediated by II angiotensin 
- Retention of water and sodium through the release of aldosterone  
These compensatory mechanisms preserve the stroke volume, increasing the 
total blood volume and arterial blood pressure. By persisting for several months 
or years, these overextended mechanisms determine excessive vasoconstriction, 
excessive water retention and increase in blood volume, with myocardial stress. 
Despite the hemodynamic benefits of these compensations, their chronic 
activation is maladaptive. The volume overload of the left ventricle and atrium 
leads to a progressive increase in left atrial pressure. Progression of heart disease 
and pump dysfunction triggers a spiral of increasing dependence on 
neurohormonal activity to maintain normal blood pressure and flow.  As long as 
the dilated left atrium remains sufficiently compliant to accept the regurgitant 
blood volume, cardiac heart failure does not develop, until the time that 
pulmonary venous pressure increases sufficiently to cause pulmonary edema, or 
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perfusion of skeletal muscles becomes severely limited. Usually, overt heart 
failure occurs years after the start of mitral insufficiency, when accompanied by 
progressive cardiac remodeling and myocardial disease. Recent studies revealed 
that most cardiac enlargement occurs in the year preceding the onset of 
congestive heart failure. (Rusch, 2009; Borgarelli & Buchanan, 2012) 
 
2.5 Clinical presentation  
 
The clinical presentation of MVD is characterized by a long pre-clinical phase, 
when the only clinical finding is a cardiac murmur in the absence of any sign of 
cardiac decompensation. 
The period between first identification of a murmur and onset of clinical signs is 
generally years. Usually the first symptom is exercise intolerance, while cough 
and dyspnea appear in the second stage of the pathology (heart failure).  
Death due to MVD is most often mediated by congestive heart failure, although 
sudden death can occasionally occur. Usually, overt heart failure occurs years 
after the start of mitral insufficiency, when accompanied by progressive cardiac 
remodeling and myocardial disease. Precipitous events are major chorda tendinea 
ruptures or the left atrium ruptures. Acute rupture of a chordae tendineae may 
lead to a catastrophic heart failure and a sudden-onset of pulmonary edema. 
Acute CHF develops as the left atrium is unable to compensate for an acute 
increase in the regurgitant volume. Another sudden and frequently fatal event is 
the left atrial tear and/or rupture. The tear can result from atrial stretch from 
mitral regurgitation or from endocardial damage caused by the jet of blood 
chronically impinging on the endocardial aspect of the left atrium. The weakened 
endocardium can split or several times the entire left atrial wall ruptures, creating 
fatal hemopericardium. If the left atrial rupture perforates the atrial septum, the 
acquired atrial septal defect usually does not cause acute left heart failure but 
leads to right heart failure eventually. Rusch, 2009; Borgarelli & Buchanan, 2012)  
2.6 ACVIM consensus 
 
In 2009 the American College of Veterinary Internal Medicine (ACVIM) 
Specialty of Cardiology consensus panel, convened to formulate guidelines for 
the diagnosis and treatment of chronic valvular heart disease. Until that moment, 
the main guidelines considered were the modified New York Heart Association 
(NYHA) and International Small Animal Cardiac Health Council (ISACHC) 
functional classification systems. These guidelines were both designed to provide 
a framework for discussing and comparing the clinical signs of patients in heart 
failure. These functional classification systems vary in their details, but both 
serve as semiquantitative schemes for judging the severity of a patient’s clinical 
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signs and to decide whether to treat or not a patient. Such categorization aids in 
teaching therapeutic protocols and constitutes a basis for stratification of 
subjects in clinical trials. The problem of these functional classification identified 
by the ACVIM Cardiology panel was that they were based on subjectively 
assessments of symptoms that can vary quickly over a short period of time.  The 
goal of the new guidelines was to link the severity of signs to appropriate 
treatments at each stage of illness. In formulating these guidelines, the consensus 
panel adapted the 2001 American College of Cardiology/American Heart 
Association classification system for the treatment of heart disease and failure in 
human patients to the management of canine chronic valvular heart disease. In 
this approach, patients are expected to advance from one stage to the next unless 
progression of the disease is altered by treatment. 
The ACVIM classification system describes 4 stages of heart disease and failure 
(Table 1) and is meant to complement the previous functional classification. 
(Atkins et al., 2009) 
 
Stage ACVIM Features 
 
A 
Patients at high risk for developing heart disease but that currently have 
no identifiable structural disorder of the heart (eg, every Cavalier 
King Charles Spaniel without a heart murmur) 
 
 
 
 
B 
 
 
B1 
Asymptomatic patients that have no radiographic or echocardiographic 
evidence of cardiac remodeling in response to chronic valvular heart 
disease. 
 
 
B2 
Asymptomatic patients that have hemodynamically significant valve 
regurgitation, as evidenced by radiographic or echocardiographic findings 
of left-sided heart enlargement 
 
 
 
 
C 
Patients with past or current clinical signs of heart failure associated with 
structural heart disease. Because of important treatment differences 
between dogs with acute heart failure requiring hospital care and those 
with heart failure that can be treated on an outpatient basis, these issues 
have been addressed separately by the panel. Some animals presenting 
with heart failure for the 1st time may have severe clinical signs requiring 
aggressive therapy 
 
 
 
 
D 
Patients with end-stage disease with clinical signs of heart failure caused by 
chronic valvular heart disease that are refractory to ‘‘standard therapy’’. 
Such patients require advanced or specialized treatment strategies in order 
to remain clinically comfortable with their disease. As with Stage C, the 
panel has distinguished between animals in Stage D that require acute, 
hospital-based therapy and those that can be managed as outpatients 
Table 1: The ACVIM classification system 
The aim of the panelists was to encourage the veterinarian to consider the risk 
factors and the prerequisites for developing MVD, in order to aid in developing 
screening programs and identify the symptomatic and the asymptomatic patients. 
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For each stage they indicate the therapeutic, dietary and diagnostic/screening 
strategies. 
2.7 Evaluation of the asymptomatic patient 
 
Murmur is the typical clinical finding of MVD in an asymptomatic dog. Point of 
maximal murmur intensity is over the left apex, with radiation dorsally and to the 
right in most cases.  The murmur intensity is classified with a grading scale (I-
VI/VI) and is not correlated to the severity of the pathology. When a murmur is 
auscultated in a dog without clinical signs, baseline testing can be offered to the 
owner to obtain a starting point for comparison at subsequent examinations. 
The client should be clearly informed of the presence of the murmur and of the 
fact that the disease may ultimately progress to cardiac heart failure.  
The minimum suggested database for these dogs includes: 
- physical examination 
- thoracic radiographs (to verify the presence/absence of cardiomegaly) 
- echocardiography (to confirm the diagnosis and evaluate heart dimension 
and function) 
- blood pressure measurement (excluding systemic hypertension) 
 
Chest radiography is recommended in all patients with MVD to assess the 
hemodynamic significance of the murmur and the comorbidity of respiratory 
diseases. Cough in dogs with MVD may be related to congestive heart failure, to 
respiratory disease and/or to the compression of the left mainstem bronchus by 
an enlarged left atrium.  
 
The electrocardiogram of a dog affected by MVD could be normal or could 
presents alterations of heart rate, rhythm and waves configuration. 
Electrocardiographic findings include evidence of left ventricular hypertrophy, 
widened P waves of left atrial enlargement, and infrequently P pulmonale.  
 
The echocardiography is the gold standard diagnostic tool for MVD. The 
diagnosis is based on assessment of morphologic alteration of mitral leaflets and 
valvular insufficiency, if present.  
The echocardiographic examination is useful to evaluate:  
- the morphologic aspect of the valvular apparatus and the movements of            
the leaflets 
- the dimension of the cardiac chambers 
- the mitral regurgitation (entity of the regurgitant blood, direction and 
velocity of the regurgitant jet) 
- the tricuspid morphologic alteration and tricuspid regurgitation, if present 
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- the myocardial contractility 
- the diastolic function 
2.8 Evaluation of the symptomatic patient 
 
Once heart failure develops, a range of clinical presentations are possible, related 
to the degree and duration of valvular dysfunction. In an acute setting, clinical 
signs are usually behavioral or pulmonary in origin, and include: cough, 
tachypnea, retching/gagging, nocturnal dyspnea, orthopnea and sometimes 
social isolation. Syncope may be the initial sign of heart disease and can occur as 
a result of significant arrhythmias, secondary to low cardiac out-put, in 
association with a vasovagal response, or following a coughing spell. (Kirk XIV). 
Some dogs exhibit decreased exercise tolerance, and weight loss for weeks to 
months before the onset of heart failure. The most frequent symptoms (cough 
and dyspnea) are common to respiratory diseases such as acute/chronic 
inflammatory/infective upper or lower respiratory diseases, neoplasia and 
cardiopulmonary filariosis. It’s therefore important to discriminate between 
respiratory and cardiologic disease.  The physical examination in the 
symptomatic patient could reveal loud bronchial sounds that can progress to 
pulmonary crackles with the onset of alveolar edema, apart from a systolic 
murmur. Often the femoral pulses are easily  palpated and prominent. Irregular 
pulse rate and strength may be noted in association with arrhythmias. Usually 
heart rate is increased and sinus arrhythmia is absent. If present, a precordial trill 
may be palpable over the apex. In the most severe cases hepatomegaly, ascites 
and jugular distension, could be visible in dogs with right-sided cardiac heart 
failure. 
During this phase the instrumental examination recommended are: 
- thoracic radiographs (to verify the presence/absence of blood stasis and 
pulmonary edema) 
- electrocardiogram (to screen the patient for possible arrhythmias 
associated to the MVD) 
- echocardiography (to confirm the diagnosis and staging) 
- blood pressure measurement (excluding systemic hypertension) 
 
Thoracic radiographs are the first diagnostic tool to use in a patient with 
respiratory symptoms, because it let the clinician to evaluate the cardiac 
silhouette, to visualize all the thoracic structures and to appreciate pulmonary 
venous dilation, if  present. The earliest characteristic findings on chest 
radiographs of  a symptomatic dog affected by MVD are mild left ventricular 
and left atrial enlargement. Left ventricular and atrial enlargement elevate the 
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trachea and carina on the lateral radiographic projection, with a decrease in 
the angle between the trachea and the 
  
 
Figure 4 Chest radiography: LL projection of the same dog affected by MVD. On the left: radiographic 
signs of advanced pulmonary edema; on the right after diuretic therapy mild interstitial opacity and 
venous distension persist. Generalized cardiomegaly, bulging of the left atrium, elevation of the trachea 
and compression of the main steam bronchus in both images.  
thoracic spine. The left mainstem bronchus may become elevated and 
compressed in cases of  moderate-to-severe left atrial enlargement. Early 
pulmonary edema is seen as a diffuse increase interstitial density, progressing 
to fluffy densities and air bronchograms with onset of  alveolar edema. 
(Rusch, 2009)  
 
The electrocardiogram of a symptomatic dog could be unremarkable or could 
presents some arrhythmias, primarily atrial arrhythmias in the advanced stages 
could be detected. Sinus rhythm or sinus tachycardia is typical of dogs with 
MVD and congestive heart failure, because of the activation of the sympathetic 
system. Conversely, ventricular arrhythmias are relatively uncommon in animals 
with compensated disease, and even in dogs with congestive heart failure 
ventricular ectopic beats or ventricular tachycardia are uncommon. Atrial 
fibrillation develops in some dogs with marked atrial dilation.  
 
The echocardiographic examination of the symptomatic patient is of great 
importance to assess the secondary lesions and the hemodynamic consequences 
of the mitral valve insufficiency. With the echocardiographic imagines we can 
assess the leaflets lesions, the left ventricular overload, the left atrial enlargement, 
the presence/absence of pulmonary hypertension and the presence/absence of 
pleural or pericardial effusions. Through the echocardiography the clinician gets 
objective informations about the cardiac status of the patient that allow to 
staging the dog and to establish the correct treatment protocol. The 
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echocardiographic informations are at the base of a precise  follow-up of the 
MVD dog and they are the foundation of the therapeutic decisions, providing 
also some great prognostic values. 
2.9 Treatment of MVD 
 
To our knowledge no medical therapy has been proven to stop the disease 
progression. The objective of the medical therapy is to improve the quality of life 
and the survival time. In the pre-clinical stage no therapy is indicated, although 
some authors recommend the use of ACE inhibitors, β-blockers and 
spironolattone. The ACE-inhibitors provide a modest vasodilators effect and an 
importantly reduction of angiotensin II and aldosterone levels, with a protective 
effect on the cardiac muscle. Their use in the asymptomatic dogs has been 
evaluated in two multicentric studies that didn’t show any significative difference 
between treated and not-treated dog, at the beginning of the clinical phase. 
(Kvart et al., 2002; Atkins et al., 2007; Locatelli, 2013) A latter study underlined a 
positive effect of ACE-inhibitor on the survival time of dogs affected by MVD. 
(Locatelli, 2013; Pouchelon, 2008 ) In the symptomatic patients, the medical 
therapy objective are to improve the general conditions of the dog, and to 
decrease the severity of the clinical signs. Diuretics and dietary sodium restriction 
are crticial for the management of congestive heart failure, in conjunction with 
ACE inhibitors. 
2.10 Mitral valve repair 
 
The ideal therapy of MVD would 
stop the progression of the valvular 
degeneration and would improve the 
valvular function. These results could 
be obtained only with surgical repair 
of the valvular apparatus, or with a 
valvular substitution before the 
beginning of the symptomatic stage. 
Nowadays the surgical approach to 
the valve is not so diffuse in 
veterinary medicine, because of 
economic and practical limitations. 
Surgical treatments for mitral regurgitation include valve replacement and valve 
repair. While these are standard therapies in human medicine , mitral valve 
surgery has been reported in comparatively few veterinary patients. The lack 
between human and veterinary medicine on surgical mitral valve repair is 
 
Figure 5 Schematic image of a cardiopulmonary 
bypass. (Uechi, 2012) 
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connected to both economic and practical reasons. For these kind of procedures 
a cardiopulmonary bypass is required. A successful cardiopulmonary bypass 
requires a dedicated team of surgeons, pefusionists, anesthesiologists, 
cardiologists, intensive care specialists and strong veterinary technicians support. 
The economic aspect is not neglectable: actually the cost of the procedures may 
be prohibitive for the vast majority of dog owners.  
Once these techniques are mastered and refined for veterinary medicine, it seems 
more probable that surgery developing catheter-based interventions to limit 
mitral regurgitation will become the preferred treatment for those that can afford 
the procedure. (Uechi, 2008) 
2.11 Genomics and MVD 
 
 The central dogma of biology is that DNA provides a template for RNA 
synthesis, which provides a template for protein synthesis. Changes within the 
DNA will affect all the downstream processes and can ultimately result in 
disease. Genomics is the study of an organism’s genome, including genes, 
regulatory sequences, and the non-coding regions of DNA. In both human and 
veterinary medicine MVD has been studied from a genetic and a genomic point 
of view. A familial occurrence of MVD has been observed in many studies in the 
human population. In some human families, MVD has demonstrated autosomal 
dominant or X-linked inheritance (Monteleone & Fagan, 1969; Devereux et al., 
1982). However, there seems to be a high degree of genetic heterogeneity of the 
disease in the human population, and the inheritance of MVD is now believed to 
be polygenic. A genome-wide association study would be a powerful approach 
for discovering genetic causes of mitral valve diseases in humans, but it would 
require a large number of cases and controls. Due to population bottlenecks in 
the past, individual dog breeds are genetically much more homogeneous than the 
human population, and within a predisposed dog breed, complex diseases are 
most likely caused by the same loci. (Lindblad-Toh et al. 2005). This increases 
the power to detect association between phenotype and genotype, and aids the 
identification of key factors in the molecular mechanisms, underlying disease 
development (Karlsson & Lindblad-Toh 2008). 
Canine MVD has been studied from a genetic point of view above all in the 
Cavalier King Charles Spaniel (CKCS) breed, because of the early onset of the 
pathology and the high prevalence of MVD among this breed. In 2011 Madsen 
et all. (Madsen et al., 2011) conducted a genome wide association study on a 
cohort of Cavalier King Charles Spaniel (139 cases and 102 controls) and they 
identified two loci associated with the development of MVD, confirming that 
the dog breed is sufficiently homogeneous with respect to the genetic 
background for a polygenic disease, to provide convincing evidence for loci 
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underlying MVD in a fairly small number of cases and controls. (Madsen et al., 
2011) In 2012 French et al. (French et al, 2012) conducted a genome-wide 
association study on 36 CKCS affected by MVD. They divided the group into 
two subgroups: early and late onset group. They didn’t identify any region of 
highly discrepant homo/heterozygosity in the two groups. Furthermore,  there 
was no evidence for loci associated with mitral valve murmur. The study of 
French et al. suggested that familial occurrence of mitral valve murmur in the 
CKCS breed is not due to a single major gene effect. 
Further studies are therefore needed to clarify the genetic aspects of MVD 
according to these preliminary results. 
 
2.12 The importance of the genes into the breeds 
 
As mentioned before some breeds are particularly predisposed to the 
development of MVD. The breed 
specificity of MVD incidence is not 
unusual for a genetic disease in dogs, as 
the breed structure of the modern 
domestic dog can lend itself to sustaining a 
detrimental genetic mutation. Breeds are 
essentially closed populations, once a 
malicious mutation develops or is 
introduced, it can readily expand 
throughout the population. As a result, the 
presence of an inherited disease in a small 
number of breeds is to be expected. What 
is unexpected in the case of MVD is that 
the majority of affected breeds display an 
average adult weight of less than 9 kg. 
There are three possible sources of common ground for the small breed dogs: 
morphologic, genetic, and historic 
ground.  
Morphologic commonalities include 
overall body size, but might also include 
skeletal shapes or components that are 
common in very small animals.  
Genetic similarities arise from the 
mutations that restrict growth. Apart 
from the genes under selection, MVD-causing mutations may be carried with 
these genes through what is commonly referred to as “hitchhiking”.  
Figure 6 Neighbor joining tree of the breeds at risk of 
MVD. Breeds are grouped in the following order 
clockwise from the top and indicated by alternating 
gray bands: toy, spaniel, scent hound, working, 
mastiff, terrier, mountain, retriever, herding, and 
sighthound. The positions of the MVD at risk breeds 
are indicated by circles on the tree. Red circle ¼ 
breed with an average adult weight less than 9 kg, 
purple circle ¼ average adult weight between 9 and 
14 kg, blue circle ¼ average adult weight over 14 kg. 
(Parker & Kilroy-Glynn, 2012) 
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Historically, it is possible that all small dogs that are affected by MVD share a 
unique common ancestor that is not directly related to size, and that they have 
inherited a set of mutations from that 
common source that have increased 
susceptibility to MVD. If a common ancestor 
exists, MVD may have been introduced at a 
very early stage of breed development, and 
may have reached a relatively high rates due to 
reductions in the gene pools of most breeds 
after development. Different genetic studies 
have identified some cluster of breeds, that 
largely correspond to specific morphologies, 
geographical origins or historical occupations 
that are shared among the breeds in the cluster. 
(Ostrander EA, Kruglyak, 2000; Parker et al., 
2010) The first group that has been identified 
was the Ancient group, that is comprised of breeds developed in Asia and 
Africa. The Ancient group is distinct from the Modern group, which is 
composed mainly by breeds of European origin.  
The Modern group is further divided into four clusters based on the genetic 
studies: 
1. The Herding-Sighthound 
2. The Mastiff-Terrier cluster  
3. The Mountain cluster 
4. The Hunting cluster  
The Hunting cluster is the most diverse one, including gun dogs, hounds and a 
subset of terriers and working dogs. The Toy breeds do not form a separate 
group, but rather display a mixture of all five groups in different proportions. 
The majority of them seem to form a cluster within the Modern group, with the 
closest breeds belonging to the Hunting cluster. Is interesting to notice that all of 
the breeds predisposed to MVD are part of the Modern cluster. If we look at the 
five primary breed groups to the high risk breeds, the Hunting group is 
doubtless the most important contributor with an average of 42% of their 
genomes coming from this ancestral cluster. (Parker et al., 2012) 
2.13 The breeds considered in the present study 
 
Cirneco dell’Etna (CdE): The first information about this breed date back to 
the V century a.c. It was thought that this breed came from the Egyptian 
pharaoh dogs, and imported in Italy by the Phoenician merchants, because of its 
great physical similarity with the dogs represented in that culture. The presence 
Figure 7 The five primary breed clusters. 
(Parker & Kilroy-Glynn, 2012) 
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of dogs similar to the CdE in the ancient Egypt 
is largely documented by bas-relief and ancient 
representations of Egyptian hunting dogs really 
close to the CdE. The subsequent studies 
demonstrated that the CdE breed is an 
autochthonous breed of the Italian  region 
Sicilia. The first traces of the presence of this 
dog in Sicilia date back to 3 millennia ago. CdE 
are represented in mosaics, literary compositions, graves and necropolis. The 
most famous and important representation is that of the Sicilian coins dating to 
the V-II century a.c., testifying the presence of this dog from very ancient times. 
The CdE dog is an hunting primitive dog, exploited for the hare hunting. We 
can therefore collocate this breed in the Hunting cluster. 
It’ is a medium size dog: medium height 46-50 cm for 
the males and 42-46 cm for the females; medium weight 
10-12 kg for the males and 8-10 kg for the females. 
The breed is poorly diffuse in Italy and really uncommon 
out of Italy. No studies about CVDs of this breed has 
been conducted before and no informations about the 
prevalence of MVD in CdE dogs exists to the author’s 
knowledge.  
 
Cavalier king Charles Spaniel (CKCS): The Cavalier King Charles Spaniel is 
one of the most popular breeds in Europe and, above all, in the United 
Kingdom. The origin of this breed date back to the first half of the 1600 d.c., 
when it was already present in England. The actual breed is a direct descendent 
of the small Toy Spaniels seen in paintings during the 16th, 17th and 18th 
centuries. During Tudor times, Toy Spaniels were quite common as ladies' pets. 
The breed gained prominence during the reign of King Charles II, because he 
had a large number of the King Charles Spaniels that followed him everywhere. 
The King Charles changed drastically its 
morphology  in the late 17th century, when 
it was interbred with flat-nosed breeds by 
Queen Mary I and William the Orange. 
They favored breeds such as the short-
nosed Pug and Japanese Chin and passed 
their characteristics down to the existing 
court's spaniels by breeding these dogs to 
King Charles Spaniels.  This breeding 
resulted in a transformation of the King 
Charles Spaniel. Until the 1920s, the 
Figure 8 V-II century a.c., Sicilian 
coins representing the CdE dog 
Figure 9 A photograph of a 
Cirneco dell'Etna dog. 
Figure 10 Vicky and Tina, two females of 
Cavalier King Charles Spaniel, tricolor coat 
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Cavalier shared the same history as the smaller King Charles Spaniel. In the early 
1920’s breeders attempted to recreate what they considered to be the original 
configuration of the breed, a dog resembling Charles II's King Charles Spaniel of 
the Restoration. In 1928 a small group of breeders of “original type” King 
Charles Spaniels united and a breed club was formed: the name Cavalier King 
Charles Spaniel was chosen for the new breed. Today the CKCS is in the genetic 
cluster of the Hunting Spaniel.  Breed standards state that height of a Cavalier 
should be between 30 to 33 cm with a proportionate weight between 4.5 to 8.2 
kg. Because of the high prevalence of MVD, the early onset and the proved 
hereditary transmission, CKCS is the most studied breed in the MVD field. The 
prevalence of the MVD in CKCS at the age of 6–7 years has been estimated in 
50%, while in dogs older than 10 years is estimated in more than 90%. In this 
breed a polygenic mode of inheritance is suggested by a strong inherited 
component. The CKCS is considered, with the dachshund, the breed with the 
highest incidence of MVD, and the breed with the youngest onset. 
2.14 Proteomics 
 
Whilst a genome provides a blueprint of an organism it does not reveal anything 
about how a gene mutation leads to the disease. Furthermore, genotype–
phenotype correlation studies have shown marked variability in the degree of 
phenotypic expression of known mutant genes, pointing to the existence of 
modifying factors. These modifications can occur at the DNA, RNA, and/or 
protein level, and it is therefore becoming clear that the functional complexity of 
an organism far exceeds that represented by its genome. Genomics is therefore 
being complemented by the newer discipline of proteomics, which has greater 
potential to understand the dynamic processes that govern cellular biology. (Lam 
et al., 2006) Proteomics aims to investigate the protein complement of the 
genome: the proteome. The term proteome was first coined by Marc Wilkins in 
1995 and describes the entire collection of proteins of an organism, including 
products arising from events such as the processing of mRNA transcripts and 
post-translational modifications. Proteomics-based studies are focused on the 
interactions of multiple proteins and their role as part of a biological system 
rather than the structure and function of one single component. Proteins are 
directly involved in virtually all cellular activities and as such influence cell 
phenotype and hence the tissue or organ. The phenotype varies under normal 
physiological conditions (e.g., cell-cycle stage, differentiation, function, and age) 
or in response to pathophysiological stresses. Chronic pathologies or acute 
injuries have a major impact on the cellular environment, changing the proteins 
and messenger RNA (mRNA) profiles. Thus, the proteome consists of 
information from protein expression, post translational modifications (PTMs), 
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processing and turnover, localization and time. The PTMs alter the chemical 
nature of an amino acid residue, that can induce a modification in the  protein 
structure, biological function and subcellular localization. For this reason the 
PTMs cannot be inferred from the genome, because they are the result of  
multifactorial mechanisms. By improving the understanding of the molecular 
mechanisms that influence the protein profiles, several pathologies may be 
detected earlier or managed more efficiently. (White & Van Eyk, 2007). The 
procedure of a proteomic study starts usually with the sample preparation,  and 
continues with protein separation, protein imaging and subsequent identification 
of proteins and peptide differentially expressed.  (Fig.6) (Cui et al., 2011) 
 
 
Figure 11 Schematic representation of a proteomic study procedures. (Cui et al, 2011) 
 Sample preparation is the first and more critical step of a proteomic study, 
because possible artefacts could be created at this stage and could interfere with 
the subsequent data analysis. The sample preparation should be performed as 
rapidly as possible to reduce the artefacts. The procedure of sample preparation 
and the choice of the chemical agents used is strictly dependent on the type of 
sample and on the type of proteins of interest.  
Protein separation is the basic step for a proteomic study. The ability to separate 
complex protein mixtures with high resolving power as well as high 
reproducibility is at the base of a good study. 2-D gel electrophoresis is the most 
used and effective method for protein separation. This technique separates the 
proteins with the combination of two different methods: proteins are separated 
in the first dimension based on their charge properties by isoelectric focusing, 
and in the second dimension based on their molecular mass. The major limit of 
the 2-D gel electrophoresis is the low reproducibility and the mass limit that 
should be in the range between 5 and 500kDa. Other separation methods are 
capillary electrophoresis and liquid chrompatography, which has been developed 
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to improve protein separation with respect to biological function or chemical 
structure.  
Protein detection and imaging follow 2-D gel electrophoresis separation. 
Proteins spots are visualized using standard protein staining methods. A digital 
image of the protein profile is obtained and it starts the image analysis using 
specialized software. Usually a control sample is used to compare the gel images 
of the experimental group and to identify differential protein expression. 
Protein identification begins with the use of a photolytic enzyme to produce 
small peptide fragments. The set of the small peptide is then subject to mass 
spectrometry (MS), which is the most used tool for protein identification.  This 
technique yields an accurate mass-to-charge ratio of each peptide fragment. 
There are different MS methods which are classified based on distinct ionization 
processes.  MS could be divided into shot-gun analysis and targeted analysis. The 
shotgun MS is a discovery-based technique, that is used mainly when no 
scientific hypothesis has been formulated about what kind of protein will be 
detected. It’s a slow method, that provides a relative quantification of the 
proteins, and it’s mainly used when the samples are abundant in protein content. 
The targeted MS, conversely, is an hypothesis-based method, that is used when 
an hypothesis about what kind of proteins will be identified has been formulated. 
It’s a fast MS that provides an absolute protein quantification, and it’s used when 
the sample has a low protein content. (Lam et al., 2006)                 
2.15 Cardiovascular proteomics 
 
The application of proteomic methods to uncover the protein function and 
structure in normal or disease states in the CV field is called cardiovascular 
proteomic. Cardiovascular proteomics can be subdivided into:  
o Mechanistic studies that aim at locating proteins which are directly and 
causally involved in functional or disease processes.  
o Biomarker studies that have the objective to locate proteins altered in 
abundance or modified in a predictable manner in response to the disease, 
with the aim of using these protein as a biomarker for that same CVDs. 
These studies are less focused on elucidating the mechanism of disease, 
instead aiming to improve clinical tools relating to the disease state. 
The basic procedure of a cardiovascular proteomic study is to compare the 
protein complements of diseased hearts or sera with controls. Any protein that 
have altered expression between the two groups can be studied further for their 
involvement in disease pathogenesis. (Edwards et al., 2008) Many CVDs have 
been object of cardiovascular proteomic studies with different results. Some 
pathologies such as dilated cardiomyopathy, atrial fibrillation, ischemia-
reperfusion injury and artherosclerosis have been more investigated than others. 
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These studies have revealed a number of proteins with altered expression during 
myocardial injury of different nature, based on the premise that death myocytes 
are released into the blood. Thanks to the identification of proteins coming from 
human myocardial tissue, a human heart 2-D gel electrophoresis protein 
database has been created. Proteome databases for canine myocardial tissues 
have been created too, by identifying and comparing homologous proteins from 
this specie to human heart 2-D gel electrophoresis database.  
 
 
2.16 Proteomics and veterinary medicine 
 
Although the application of proteomics in veterinary medicine has lagged behind 
human medical uses, an increasing and relevant number of studies have been 
conducted on these items. The investigation on farm animals is the field were 
proteomics have been more applied. Proteomics research in bovine medicine is 
mainly focus on bovine mastitis, the most frequent and most costly production 
disease in dairy cows. In pig medicine the pathogenesis of several viral disease 
has been explored by proteomics, while in horses the articular disorders and the 
equine recurrent uveitis are the main items of proteomics research. The use of 
proteomics in companion animals studies is less extensive than that for farm 
animals. Infectious and neoplastic diseases are the applications where proteomics 
approaches have been more exploited.  For the infectious diseases like 
Leishmania and Rabies, proteomics has been used in an attempt to identify novel 
antigens for vaccine production and diagnostic development, while for the 
oncologic field proteomics has been applied in the research of potential 
biomarkers of neoplastic disease.  (Ceciliani et al., 2014) 
At the same way, the cardiovascular medicine searched for different type of 
biomarkers for dogs and cats, producing a remarkable number of studies and 
identifying a relevant number of cardiovascular biomarkers for the dogs and the 
cats. In a recent review article Boswood proposed a system for categorizing 
biomarkers used in congestive heart failure: 
1. Markers of myocyte injury 
2. Markers of myocyte stress 
3. Markers of remodeling 
4. Markers of endothelial dysfunction 
5. Markers of inflammation 
6. Neurohormonal markers 
 
Within the markers of myocite injury the cardiac troponins I and T have been 
widely used in veterinary medicine and in clinical practice. Troponins I and T are 
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intracellular proteins that  are not normally present in detectable concentrations 
in the circulation. The presence of  high concentrations of troponins I and T in 
the serum is associated with myocardial injury. Currently, the principal clinical 
use of concentrations of troponins in human patients is for the detection of 
myocardial  ischemia secondary to coronary vascular disease, primarily 
atherosclerosis. This is not a condition that occurs commonly in veterinary 
patients; however troponins have been measured in a multitude of different 
situations in dogs and cats to evaluate the effects of both cardiac and 
extracardiac diseases on myocardial integrity.(Boswood, 2009) Among the 
biomarkers of myocyte stress, the natriuretic peptides are the most studied, both 
in human and in veterinary medicine.  All natriuretic peptides share a common 
phylogenetic background but, due to differences in receptor-binding affinities, 
they have evolved into different hormones with clear distinct functions. B-type 
natriuretic peptide (BNP) is the most studied member of the natriuretic peptide 
family, and, together with its cleavage equivalent amino-terminal proBtype 
natriuretic peptide (NT-proBNP), they have emerged as important 
cardiovascular serum markers. The mechanism at the base of their use as a 
serological biomarker of myocardial stress is that, after stimulation of 
cardiomyocytes in cardiovascular diseases, preproBNP production is up-
regulated, resulting in an increase of the BNP and NT-proBNP concentrations 
in the circulation. Accordingly, there has been a great interest in their use for the 
diagnosis or exclusion of heart failure, as well as for prognostic and therapeutic 
applications. (Roland et al., 2009) 
2.17 Proteomics and mitral valve disease: state of the art 
 
Mitral valve disease is the most common heart valvular disease in humans in 
Europe and United States and it’s the primary naturally occurring heart disease in 
dogs(Lacerda et al., 2009). According to the great scientific interest that MVD 
has reached in the last few years, the scientific studies about this item are 
increasing in number since 1944. Being the disease pathologically identical in 
humans and dogs, a common pathogenesis has been suggested in these species. 
For this reason, canine MVD has been used as a model for human medicine. 
The scientific community is involved in searching new therapeutic approach and 
new diagnostic tools that could offer a better understanding and a more precise 
management of the pathology. In this context the first proteomic study on MVD 
has been conducted in 2009 by Lacerda et al. The objectives of the study were to 
develop proteomic methodology suitable for analysis of extracellular matrix-rich 
heart valve tissues, and survey over and under-expressed proteins that could 
provide mechanistic clues into the pathogenesis of MVD. The mitral leaflets of 
12 dogs were obtained post-mortem and classified macroscopically and 
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microscopically 
as normal (four 
dogs), early 
MVD stage (four 
dogs) and late 
MVD stage (four 
dogs). 
Epidemiologic 
data (breed, sex, 
age, gender) were 
collected, and 
then three-way 
proteome 
comparisons of normal, early-stage and late-stage myxomatous valve regions 
were performed. A shotgun proteomic analysis was used for protein 
quantification. Proteins were classified based on function, and clustered 
according to differential expression. More than 300 proteins were identified, and 
117 of these proteins were differentially expressed.  
Protein profiles showed that early- and late-stages valves were closely related, 
and this finding suggested that the proteomic changes of the leaflets appear in 
the eraly onset of the pathology, and persist till late-stage. 
 
The differentially expressed 
proteins were: 
-structural proteins 
-proteins involved in the 
metabolism  
-proteins involved with calcium 
binding and calcification. 
 
The overall expression patterns 
were for proteins to be fully 
downregulated or upregulated in 
myxomatous valves, or 
upregulated in early-stage and 
downregulated in late-stage 
disease. The degree to which 
these expression patterns could 
be explained by differences in cellular events versus relative abundance of 
cellular/extracellular proteins was unclear. It is doubtless that differentially 
Figure 12 Protein expression in normal, early-stage and late-stage myxomatous 
valves. (Lacerda et al., 2009) 
Figure 13 Functional classification of proteins differentially 
expressed between canine normal and myxomatous mitral valves 
identified based on homology with human proteins with known 
function. (Lacerda et al., 2009) 
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expressed proteins identified in this study provided a basis for othere 
investigations into the pathogenesis of canine and human MVD. 
In 2013 the second proteomic study on MVD and the first one conducted on 
serum samples was published by Tan et al. (Tan et al., 2013) Peripheral venous 
blood samples were collected from 166 human patients affected by MVD and 66 
normal patients, in order to search for clinical biomarkers that may aid in 
detecting or risk stratifying this condition. All the epidemiological data and the 
echocardiographic measurements were recorded. The samples were trated and 
underwent the proteomic procedures to obtain the differential expressed 
proteins (sample preparation, protein quantitation, labeling of the samples, mass 
spectrometry, database search of the data and quantitation of the proteins 
differentially expressed). 
Three proteins were identified to be differentially expressed between MVD and 
not MVD patients: platlet basic protein (PBP), haptoglobin and complement c4 
were down-regulated in MVD cases, while fibronectin was up-regulated in MVD 
patients. Fibronectin up-regulation was not confirmed with ELISA testing and it 
was tought to be an outlier effect. 
Haptoblogin is an hemoglobin-binding plasma protein. Since haptoglobin is not 
recycled after clearance of the hemoglobin–haptoglobin complex, the storage 
pool is depleted and low serum levels are characteristic of hemolytic states. 
Hemolytic anemia hasn’t been associated with MVD, but it’s possible that the 
altered leaflets and the increased valvular shear stress lead to hemolysis and 
hemoglobin release into circulation, depleting the haptoglobin storage pool. 
Platelet basic protein (PBP) is a chemokine localized predominantly in platelets, and 
released upon platelet activation. PBP functions as signaling molecules and as 
anti-microbial peptides. It is possible that decreased plasma PBP could 
contribute to the increased risk of infective endocarditis associated with MVD. 
Reduced PBP may also implicate altered platelet function in MVD patient. The 
degree of platelet dysfunction may be related to the severity of MR. These thesis 
has been object of discussion, providing conflicting data on the exact relation 
between platelet dysfunction and MVD.  
Complement component c4b resulted down-regulated in MVD cases. Complement 
c4b is part of the complement system, the most important component of 
humoral autoimmunity in the natural defense mechanism. It is possible that 
chronic infections could create immune complexes over a long period of time, 
resulting in a natural depletion of its components.  The complement system is 
also involved in myocardial cell injury related to ischemia and reperfusion, and in 
the pathogenesis of atherosclerosis.  
All of these three proteins differentially expressed have a presumptive role in the 
pathogenesis of MVD, so that further studies are needed to confirm there 
preliminary results. In this researches appeared clear that it is necessary to 
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correlate biomarker levels with clinical phenotype and outcomes in larger, more 
diverse populations, to establish appropriate threshold levels upon which to base 
clinical decision-making.  
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Objective 
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3.1 Objective  
 
The objective of the present study was to assess the prevalence, the clinical and 
the echocardiographic presentation of MVD in two groups of two different 
breeds of dogs: Cirneco dell’Etna, a breed never considered before for any 
CVDs studies, and Cavalier King Charles Spaniel, the most important breed for 
MVD research.  
Furthermore, we tried to identify and study serum proteins of the same patients 
differentially expressed in healthy dogs and in dogs affected by MVD from mild 
to severe stages. The proteomics results were then matched with the clinical 
features, to find a connection available in the clinical practice.  
 
The goals of the present study were: 
- To assess the prevalence of MVD in the Cirneco dell’Etna breed 
- To provide a global scanning of the serum  protein modifications and to find a 
serological biomarker that could be useful to better define the diagnosis, the 
therapy, and the clinical presentation of the MVD.  
 
Moreover, taking into account that the canine model is of great significance for 
the human MVD, the present study, that has been conducted on a well classified 
canine model, could be an interesting starting point for further studies in human 
medicine. 
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CHAPTER 4 
 
 
Materials and methods 
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4.1 Materials and methods 
 
This is a prospective study that has been conducted on private-owned dogs 
recruited from the Cardiologic Service of the Department of Veterinary Science 
and Public Health, University of Milan, from January 2011 to January 2014, in 
cooperation with the proteomic laboratory ISILS-UNIMI.  
Two groups of dogs have been selected, based on the following inclusion 
criteria: 
o Healthy dogs of the selected breeds without any detectable pathology at 
the moment of the inclusion in the study 
o Dogs of the selected breeds affected by MVD, without any other 
detectable pathology  at the moment of the inclusion in the study 
 
The exclusion criteria were: 
o Dogs of any breed different from the breeds selected 
o Mix-breed dogs 
o Dogs affected by any detectable pathology 
o Dogs affected by any other cardiac pathology different from MVD 
 
The breeds selected were: 
 
o Cirneco dell’Etna 
o Cavalier King Charles Spaniel  
4.2 Step 1 
 
From January 2011 to July 2012, we included in the study all the Cirneco 
dell’Etna dogs that entered the Cardiologic Service of the Department of 
Veterinary Science and Public Health. Each dog has been subjected to a 
complete physical examination, an echocardiography and a blood sampling.  
Physical examination: it was aimed at evaluating the general physical condition of 
the dogs, checking the skin, the lymph nodes dimension and texture, the color of 
the mucous membranes, the thoracic and cardiac auscultation, the abdominal 
examination and the body temperature. It was paid particular attention to the 
cardiovascular system.  
Cardiovascular system evaluation: the cardiovascular system was evaluated 
checking the mucous membranes, capillary refilling time, heart rate, heart 
rhythm, respiratory rate, presence/absence of a murmur, type and intensity of 
the murmur if present, grade of the murmur(I-VI/VI), type of pulse and 
pulmonary auscultation. 
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The anamnesis and the clinical data were collected on a database support for 
each patient. 
The echocardiography  was then performed on the awake dogs, according to the 
echocardiographic guidelines of the 
American Society of Echocardiography 
(Thomas, et al. 1993).  
The echocardiographs were performed 
with an Esaote machine MyLab 50gold 
(Firenze, Italia), with phased array 
multifrequency probes. 
Two-dimensional and M-mode 
echocardiography were used to define 
valve morphology and structures, 
including the type of lesions and the 
presence/absence of valvular prolapse. 
The B-mode technique was used to 
study the anatomy of the valves. With 
the B-mode images it’s possible to identify valvular thickening and valvular 
prolapse into the atria, from the first stage of disease. With advancing disease the 
valve becomes progressively thicker, and left atrial and ventricular enlargement is 
noted. Rupture of a chordae tendineae leads to a flail mitral leaflet with chaotic 
valve motion and a tip of the leaflet pointing dorsally into the left atrium in 
systole.  
The M-mode technique was used to study the myocardial contractility, the 
mitral valve motion and to measure the left ventricle dimensions.  
Measurement of chamber size and function 
help to define both the chronicity and the 
extent of remodeling.   
The assessment of valvular insufficiency 
was made using all echocardiographic 
modalities to assess the significance and 
severity of the leak.  
Color-flow Doppler rapidly identifies the 
presence of regurgitation. Attention to the 
jet area with respect to the receiving 
chamber, the width of the jet at its orifice, 
and the area of flow convergence adds 
accuracy in assessing the severity of 
regurgitant volume.  
Spectral Doppler helps to measure the regurgitant volume and fraction, and is 
used to measure regurgitant orifice area.  
Figure 14 M-mode image of a dog left ventricle at the level 
of the papillary muscles. Short axis. 
Figure 15 B-mode image, right parasternal long-
axis view- Color-flow Doppler identified the mild 
mitral regurgitation 
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Pulsed-wave Doppler and Continuous-wave Doppler assess hemodynamic 
severity by evaluating spectral trace density, velocity of flows, and flow profiles.  
 
The examination consisted of standard views in both right and left parasternal 
location. The right parasternal location was used to provide the following 
standard images: 
 
- Right parasternal  long-axis view 
- Right parasternal long-axis view optimized for the left ventricular outflow 
tract 
- Right parasternal short axis view optimized for the papillary muscles 
- Right parasternal short axis view optimized for the mitral valve 
- Right parasternal short axis view optimized for the left auricle/aorta ratio 
(base of the heart) 
- Right parasternal short axis view optimized for the pulmonary artery 
 
 
 
 
Figure 16 Images from Thomas et al, 1994. On the right: schematic representation of a right parasternal long axis 
view echocardiographic image. On the right: schematic representation of a short axis right parasternal view at 
different levels. RV= right ventricle; TV= tricuspid valve; RA= right atrium; LV= left ventricle; MV= mitral valve; 
LA= left atrium; VS= ventricular septum; LVW= left ventricular wall; CH= chordae tendinae; PM= papillary 
muscle; AO= aorta; RPA= right pulmonary artery; LPA= left pulmonary artery; LC= left coronary cusp; RC= right 
coronary cusp; NC= non coronary cusp; APM= anterior papillary muscle; PPM= posterior papillary muscle; Rau= 
right auricular; PA= pulmonary artery; CaVC= caudal vena cava.  
 
 
 
The retrosternal view was used to assess the aortic flow velocity. 
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 The left parasternal location was used to provide the following standard images: 
- Left parasternal long-axis two chamber view 
- Left parasternal long-axis four chamber view 
 
 
The spectral Doppler and the colour Doppler were used for the assessment of 
possible valvular regurgitation and for the quantification and study of the blood 
flow through the valves.  
 
Based on the physical examination data and 
based on the echocardiographic response, we 
included in the study all the normal CdE dogs, 
and all the CdE dogs affected by MVD. All the 
patient affected by any heart disease different 
from MVD were exluded. All the patients 
affected by any systemic disease were excluded. 
 
Each patient included in the study was then 
allocated in one of the following groups: 
 
Normal dogs (N): no physical and no 
echocardiographic signs od MVD 
 
Very slightly affected dogs (VS): asymptomatic 
dogs, with a cardiac murmur of I grade, and a 
mild Doppler evidence of mitral regurgitation, 
with mild mitral valve prolapse and without any 
echocardiographic signs of leaflets thickening 
(corresponding to ACVIM stage b1) 
 
Mild affected dogs (M): asymptomatic dogs, with a cardiac murmur from 
II to VI grade, and echocardiographic evidences of MVD, with mitral 
valve prolapse and valvular thickening (corresponding to ACVIM stage of 
heart failure b1 and b2) 
 
Severely affected dogs (S): symptomatic dogs, with physical signs of heart 
failure and echocardiographic evidences of MVD (corresponding to 
ACVIM stage of heart failure c and d) 
 
Figure 17 Images from Thomas et 
al, 1994. Schematic representation 
of a left apical view and a five 
chamber left parasternal view. 
RV= right ventricle; RA= right 
atrium; LV= left ventricle; LA= left 
atrium; AS= atrial septum; AO= 
aorta. 
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Peripheral venous blood samples were taken from each patient after a 12 hour 
fasting. The samples were collected in a EDTA tube (2.5 ml blood) and in two 
serum tubes (2.5 ml of blood for each tube). The EDTA tube was used for a 
cellular blood count of each patient, and it was than eliminated. The samples in 
the serum tube were separated by centrifugation at 3000 ×g for 5 minutes and 
the plasma aliquoted. The total protein content and the blood glucose of each 
sample was immediately evaluated. The remaining plasma was stored at −18 °C 
until further analysis. 
 
4.2 Step 2 
 
 
Eight serum samples were selected for the proteomic analysis, in order to have 2 
samples for each group. The serum samples were analyzed through 2D 
electrophoresis followed by Maldi TOF MS analysis for protein identification. 
Two sera from normal dogs, two from very slightly affected, two from mild 
affected and two from severely affected dogs were used for proteomic analysis. 
Briefly, protein concentration in all samples was determined using 2D Quant Kit 
(GE Healthcare). GE Healthcare immobilized pH gradient (IPG) strips 
(Immobiline DryStrip pH 3-10NL, 7 cm) were rehydrated overnight in 125µl of 
buffer containing 7 M urea, 2 M thiourea 2% CHAPS, 1% DTT, 2% ampholine 
pH 3.5–10. 100 µg of protein sample were loaded on each IPG strip using cup 
loading at the cathodic side.(20) Isoelectric focusing was performed using an 
Ettan IPGphor III IEF system (GE Healthcare) at 20° C with a current of 120 
µA per strip. For IEF the following protocol was used: 30 V (4 h), 50 V (3 h), 
100 V (3 h), 500 V (3 h), 1000 V (3 h), 3000 V (3 h), 4000 V (3 h), 6000 V (3 h) 
and 8000 V (8 h).(21) After the first dimension, IPG strips were equilibrated 
twice with a solution containing 6M urea, 2% SDS, 50 mMTris–HCl pH8.8 and 
30% glycerol, for 15 min, under gentle stirring. For the first equilibration step 
was used 1% DTT and for the second 2.5% iodoacetamide. The second 
dimension was performed using homemade 10% acrylamide vertical SDS-PAGE 
slab gels on a mini-protean tetracell (BioRad). IPG strips were put on top of the 
SDS gels which were poured up to 1 cm from the top of the plates and then 
sealed with 1 ml of a solution containing 0.5% low-melting-point agarose diluted 
in hot SDS running buffer (25 mMTris–HCl pH 8.3, 192 mM glycine, 0.1% 
SDS). Molecular weight protein markers (Invitrogen) were applied on one end of 
the IPG strips. In the second dimension, gels were run at 15 mA per gel, for 20 
min and then at 40 mA per gel, until the bromophenol blue front-line came out 
of the gel. After runs, gels were stained with colloidal Coomassie and digitalized 
with PharosFX Plus Laser Imaging System (BioRad). 
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Image and statistical analysis were performed using Progenesis SameSpots 
(Nonlinear Dynamics).  
4.3 Step 3 
 
From September 2012 to January 2014, we included in the study all the Cavalier 
King Charles Spaniel dogs that entered the Cardiologic Service of the 
Department of Veterinary Science and Public Health. The dogs underwent the 
same clinical evaluation of the Cirneco dell’Etna dogs: a complete physical 
examination, with particular attention to the cardiovascular system, and an 
echocardiography were performed.  
The echocardiography was performed providing the standard images 
recommended by the echocardiographic guidelines of the American Society of 
Echocardiography. The following echocardiographic parameters were then 
taking into account by the present study: 
 
 Left ventricular inner dimension in systole and in diastole (LVIDs e 
LVIDd) 
 End diastolic volume index (EDVI): 
    {[7/ (2,4+LVIDd/10)] X [(LVIDd/10)³)/BW ]} 35 
 End systolic volume index(ESVI): 
     {[7/ (2,4+LVIDs/10)] X [(LVIDs/10)³)/BW ]} 35 
 Left atrium/aorta root ratio (La/Ao ratio) 
 Fractional Shortening (FS%) 
[ (LVIDd-LVIDs)/LVIDd] X 100 
 Ejection Fraction (EF%)  
[ (End Diastolic Volume – End Systolic Volume)X 100/EDV 
 
 
 LVIDs and ESVI are measurement indicative of the systolic dimension of the 
left ventricle, and they are a reflection of the systolic function. The LVIDd and 
EDVI are indicative of the diastolic dimension of the left ventricle and they are 
used to evaluate the presence or absence of left ventricular overload. These 
measurements reflect maximum ventricular filling when the heart is relaxed. The 
La/Ao ratio is indicative of the left atrial dilation subsequent to the  mitral 
regurgitation, and is an important prognostic factor. Dogs with La/Ao ratio 
greater than 1.7 have been found to be a poor prognostic indicator for survival.  
The FS is the most common echocardiographic measurement of left ventricular 
function. It’s influenced by the preload, the afterload and the contractility. The 
EF represents the percent of blood volume ejected from the left ventricle during 
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systole. The load dependency of EF% and FS% explains why, in the case of 
MVD, impaired myocardial function may be associated with normal values of 
these indices. Therefore, most authors agree that normal values for FS% or 
EF% in dogs with severe MR suggest systolic myocardial failure 
 
The dogs selected were allocated into three categories based on the physical 
examination and on the echocardiographic data:  
 
o Normal dogs (N): no physical and no echocardiographic signs od MVD 
 
o Mildl affected dogs (M): asymptomatic dogs, with a cardiac murmur and 
echocardiographic evidences of MVD (corresponding to ACVIM stage of 
heart failure b1 and b2) 
 
o Severely affected dogs (S): symptomatic dogs, with physical signs of heart 
failure and echocardiographic evidences of MVD (corresponding to 
ACVIM stage of heart failure c and d) 
 
The decision to divide the CKCS population in 3 subgroups and not in 4 
subgroups was based on the proteomics results obtained from the CdE group: 
no significative differences were found between the VS group and the other 
groups, so that it was decide to incorporate the mildly affected subjects in an 
only one group (M group). Peripheral venous blood samples were taken from 
each patient after a 12 hour fasting. The sample were collected in two serum 
tubes (2.5 ml of blood for each tube). The samples were separated by 
centrifugation at 3000 ×g for 5 minutes and the plasma aliquoted were stored at 
−18 °C until further analysis. 
From the starting group of 24 dogs, an homogeneous group of thirteen dogs was 
created in order to have a peer distribution of normal, mild and severe affected 
dogs. It was not possible to have five dogs of each category because just three 
dogs in the severe stage were recruited, being the dogs with the highest mortality 
rate. 
 
 
4.4 Step 4 
Six serum samples were selected for the proteomic analysis, in order to have 2 
samples for each group. The serum samples were then analyzed through 2D 
electrophoresis followed by Maldi TOF MS analysis for protein identification. 
Two sera from normal dogs, two from mild affected and two from severely 
affected dogs were used for proteomic analysis. 
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Proteomic analysis was performed as described above in section 4.2. 
 
 
4.5 Descriptive and statistical analysis 
All calculations were done using SAS statistical software (SAS version 11 SW; 
SAS Institute, Cary, North Carolina, USA). Descriptive statistics were used for 
age, gender, weight and all the echocardiographic variables considered. 
Descriptive data are reported as mean ± S.D. or percent as appropriate. 
Normality of the distributions was examined using the Shapiro-Wilk test (W> 
0,05). Differences between the categories of disease severity were determined by 
analysis of variance (ANOVA) and the Student’s t Test for the normal data, and 
with the Kruskal-Wallis test for non-parametric variables or non-parametric 
Wilcoxon Each Pair test for the not normally distributed variables.  
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5.1 Results             
 
Cirneco dell’Etna group 
 
From January 2011 to July 2012, fourteen Cirneco dell’Etna dogs entered the 
Cardiologic Service of the Department of Veterinary Science and Public Health, 
University of Milan. Considering the total number of dogs that were examined 
by the Cardiologic Service (302 dogs) during the same period, the CdE 
represented the 4.6%. After the clinical and the echocardiographic examination 4 
dogs (29%) were classified as normal, nine dogs (64%) were affected by MVD 
and in one case (7%) it was diagnosed a congenital heart disease (pulmonic 
stenosis, PS). Considering the dogs affected by MVD, 3 dogs were very slightly 
affected, 3 were mildly affected and 3 dogs were severely affected: one of these 
dog died during the study period because of congestive heart failure. From the 
starting group of 14 dogs, a group of twelve dogs was created for the proteomic 
and clinical analysis, because the subject affected by SP and the death subject 
were eliminated.  
 
The Cirneco dell’Etna group was therefore composed of twelve dogs. Seven 
dogs were female (58%), two were spayed females (17%) and three were males 
(25%).The medium weight was (kg ± standard deviation) 11.7 kg ± 0,95 while 
the medium age was (years ± standard deviation) 7.5 years ± 4.6. 
All the variables resulted normally distributed (W>0,05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Four dogs were allocated in the normal (N) group, three dogs were allocated in 
the very slightly affected group (VS), three dogs were allocated in the mildly 
affected (M) group and 2 dogs were allocated in the severely affected (S) group. 
Gender distribution 
CdE dogs 
F
SF
M
Chart 1 Pie Chart of the gender 
distribution in the CdE group 
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ID 
num. 
Sex Age Weight Echocardiographic diagnosis Group 
1 F 1 12 Normal N 
2 M 2 12.3 Normal N 
3 F 6 12 Normal N 
4 F 2 11.5 Normal N 
5 SF 8 13.2 Mild mitral insufficiency VS 
6 F 7 11.8 Mild mitral insufficiency VS 
7 M 6 12.2 Mild mitral insufficiency VS 
8 F 7 12 Mild mitral insufficiency with mitral 
leaflets prolapse and valve thickening  
M 
9 F 13 12.8 Mild mitral and tricuspid insufficiency M 
10 M 12 10 Mild mitral and tricuspid insufficiency M 
11 F 12 10 Severe mitral and tricuspid 
insufficiency 
S 
12 SF 15 11.6 Severe mitral and tricuspid 
insufficiency, pulmonary hypertension 
S 
Table 2 Cirneco dell'Etna group 
 
- N (Normal) group 
The N group was composed of 4 dogs: 3 female (75%) and 1 male (25%). 
The medium age was 2.7 years ± 2.21 and the medium weight was 11.95 kg ± 
0.33 
 
-    VS (Very slightly affected) group 
 
The VS group was composed of 3 dogs: one female (33%), one spayed 
female (33%) and one male (33%). The medium age was 7 years ± 1 and the 
medium weight was 12.4 kg ± 0.7. 
 
- M (Mildly affected) group 
The M group was composed of 3 dogs: 2 female (67%) and 1 male (33%).  
The medium age was 10,6 years ± 3.2 and the medium weight was 11.6 kg ± 
1.4. 
 
- S (Severely affected) group 
The S group was composed of 2 dogs: 1 female and 1 spayed female. The 
medium age was 13.5 years ± 2.1 and the medium weight was 10.8 kg ± 1.13. 
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Chart 2 Box-plot of the age distribution in the 4 CdE subgroups. Data are presented as 
upper and lower quartiles and interquartile range (box), the median (horizontal line), 
and the maximum and minimum values (crosses). 
 
 
 The ANOVA of the age in the 4 groups was performed (F= 0.0023*) and 
then the significance of difference between the patient groups of the same 
variable was tested with the Student’s t test.   
 
 
 
 
 
 
 Chart 3 ANOVA and Student's t test graphic representation of the age distribution in the 4 groups 
of CdE dogs. P values  for each couple are reported in the table. 
 
 
Proteomic analysis was performed in the four different experimental groups 
as previously described. Two sera from normal dogs, two from very slightly 
N VS M S
Age of the different CdE groups 
 
Level 
 
- Level 
 
p- value 
G N 0.0006* 
M N 0.0019* 
G VS 0.0144* 
VS N 0.0411* 
M VS 0.0854 
G M 0.2121 
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affected, two from mild affected and two from severely affected dogs were 
analysed through 2D electrophoresis followed by Maldi TOF MS analysis for 
protein identification. 
Among analysed proteins two of them were found to be differentially 
expressed and were successfully identified through MS analysis. The first one, 
spot number 2092, was found to be a protease inhibitor (serpin peptidase 
inhibitor, alpha-1 antiproteinase, antitrypsin) and its expression was increase 
according to the severity of the pathology. The detail of the trend for alpha-1 
antiproteinase is shown in chart 4. On the other hand it was found a strong 
downregulation of the representation of complement C3 protein according to 
the severity of the pathology. This trend is shown in chart 5, both differential 
representation of this protein was statistically significant with a p-value lower 
than 0,05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure y 
 
Chart 4: alpha-1 antiproteinase trend in the different stages of pathology 
Chart 5: Complement C3  trend in the different stages of pathology 
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Cavalier King Charles Spaniel group 
 
From September 2012 to January 2014, 24 Cavalier King Charles Spaniel entered 
the Cardiologic Service of the 
Department of Veterinary Science and 
Public Health, University of Milan. 
Considering the total number of dogs 
that were examined by the Cardiologic 
Service (341 dogs) during the same 
period, the CKCS represented the 7%. 
Eight CKCS (33%) were classified as 
normal after the clinical and the 
instrumental evaluations, one dog (4%) 
had a congenital heart disease (patent 
ductus arteriosus, PDA), and 15 patients 
(63%) were classified as affected by 
MVD. The medium age was 4.8 years ± 3.2 and the medium weight was 8.7 kg 
± 2.4. Thirteen dogs were male (54%), nine dogs were female  (38%) and two 
dogs were spayed female (8%). Nine of the 15 CKCS affected by MVD were 
mild affected, and six dogs were severely affected: two of them died during the 
study period because of congestive heart failure. From the starting group of 23 
dogs, an homogeneous group of thirteen dogs was created in order to have a 
peer distribution of normal, mild and severe affected dogs. It was not possible to 
have five dogs of each category because just three dogs in the severe stage were 
recruited after the death of two patients, being the dogs with the highest 
mortality rate.  
 
The group selected had the following distribution: five dogs were female (38%), 
two dogs were spayed females (15%) and six dogs were males (46%). The 
medium weight was 8.8 kg ± 1.8 and the medium age was 4.4 years ± 3.13.  
The medium LVIDd was 31.5 mm ± 4.91 and the medium LVIDs was 19.3 mm 
± 4.65. The medium EDVI was 88 ± 32 and the medium ESVI was 25 ± 12. 
The medium La/Ao ratio was 1.48 ± 0.5. The medium FS% was 38 ± 9 and the 
medium EF% was 68 ± 12. 
The normal distribution of all the continuous variables was tested with Shapiro-
Wilk test. Age, weight, LVIDd, EDVI, FS% and EF% were normally distributed 
(W> 0,05), while LVIDs, ESVI and La/Ao were not normally distributed.  
 
 
 
Gender distribution 
CKCS 
F
FS
M
Chart 6 Pie Chart of the gender distribution in 
the CKCS group 
54 
 
 
 
For the not normally distributed variables non-
parametric tests were then used (Kruskal-Wallis and 
Wilcoxon), while for the normally distributed data 
parametric tests were used for the analysis of 
variance (ANOVA and Student’s t). 
 
 
 
 
ID num. Sex Age Weight Echocardiographic diagnosis Group 
1 F 1,5 4,9 Normal N 
2 F 0,8 6,6 Normal N 
3 FS 5 10 Normal N 
4 M 1 8 Normal N 
5 F 3,5 6,8 Normal N 
6 M 6 9,6 Mild mitral insufficiency M 
7 M 5 10 Mild mitral insufficiency M 
8 M 5 14,4 Mild mitral insufficiency M 
9 F 1 4,4 Mild mitral and tricuspid insufficiency M 
10 F 3 12,7 Mild mitral and tricuspid insufficiency M 
11 FS 11 11,1 Severe mitral and tricuspid 
insufficiency, pulmonary hypertension 
S 
12 M 6 8,6 Severe mitral and tricuspid 
insufficiency, pulmonary hypertension  
S 
13 M 9 8,15 Severe mitral and tricuspid 
insufficiency, pulmonary hypertension 
S 
Table 4 Cavalier King Charles group 
 
- N (Normal) group: 
The N group was composed of five dogs: 3 females, 1 spyed female and 1 male. 
The medium age was 2.36 years ± 1.8 and the medium weight was 7.2 kg ± 1.8. 
All the medium echocardiographic data ± SD are reported in the following table. 
 
 
 
 
Variable W 
LVIDs 0.0016 
LVIDd 0.8552 
ESVI 0.0074 
EDVI 0.3629 
La/Ao 0.0046 
FS% 0.1091 
EF% 0.3883 
Table 3 W-values for each 
echocardiographic variable 
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N group LVIDd 
(mm) 
LVIDs 
(mm) 
EDVI 
normal 
value < 
100 
ml/m3 
ESVI 
normal 
value < 
30 
ml/m3   
La/Ao 
normal 
value < 
1.5 
FS% 
normal 
value 
> 20% 
EF% 
normal 
value 
> 40% 
Medium 
± SD 
29 ± 2.2 20 ± 
6.2 
72 ± 13 24 ± 
8 
1.1 ± 
0.2 
35 ± 2 66 ± 3 
Table 5 Mean echocardiographic variables ± SD for the N CKCS group 
- M (mildly affected) group: 
The M group was composed of five dogs: 3 males and 2 females. 
The medium age was 4 years ± 2 and the medium weight was 10 kg ± 3.8 
All the medium echocardiographic data ± SD are reported in the following table. 
 
M 
group  
LVIDd 
(mm) 
LVIDs 
(mm) 
EDVI 
normal 
value < 
100 
ml/m3 
ESVI 
normal 
value < 
30 
ml/m3   
La/Ao 
normal 
value < 
1.5 
FS% 
normal 
value 
> 20% 
EF% 
normal 
value 
> 40% 
Medium 
± SD 
30.4 ± 
6.2 
19.5 ± 
4.6 
82 ± 38 29± 19 1.3 ± 
0.3 
36 ± 
11 
64 ± 
17 
Table 6 mean echocardiographic variables ± SD for the M CKCS group 
- S (severely affected group): 
The S group was composed of 3 dogs: 2 males and 1 spayed female.   
The medium age was 8.6 years ± 2.5 and the medium weight was 9.2 kg ± 1.5. 
All the medium echocardiographic data ± SD are reported in the following table. 
 
S group  LVIDd 
(mm) 
LVIDs 
(mm) 
EDVI 
normal 
value < 
100 
ml/m3 
ESVI 
normal 
value < 
30 
ml/m3   
La/Ao 
normal 
value < 
1.5 
FS% 
normal 
value 
> 20%  
EF% 
normal 
value 
> 40% 
Medium 
± SD 
36.6 ± 
2.2 
17.7 ± 
1.7 
126 ± 6 20± 3 2.3 ± 
0.7 
46 ± 
10 
77 ± 
11 
Table 7 Mean Echocardiographic variables ± SD for the S CKCS group 
 
The ANOVA of the age between the 3 groups was performed (F=0.0056*) and 
then the significance of difference of the same variable between the groups was 
tested with the Student’s t test. A statistically significant difference was found 
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between the S and the other two groups, while no difference was found between 
the M and the N group. 
 
  
 
Chart 7 Box-plot of the age distribution in the 3 CKCS subgroups. Data are presented as upper and lower 
quartiles and interquartile range (box), the median (horizontal line), and the maximum and minimum 
values (crosses). p-values for each couple are reported in the correspondent table (Student’s t test). 
 
The ANOVA of the variable EDVI between the 3 groups was performed 
(F=0,0417*). The significance of difference between patient groups of the 
variable EDVI was studied with the Student’s t test and resulted statistically 
different only between the N and the S group. No difference was found between 
the other groups.  
 
 
 
Chart 8 Box-plot of the EDVI values distribution in the 3 CKCS subgroups. Data are presented as upper 
and lower quartiles and interquartile range (box), the median (horizontal line), and the maximum and 
minimum values (crosses). p-values for each couple are reported in the correspondent table (Student’s t 
test). 
 
 
0
5
10
15
N M S
Age of the different 
CKCS groups 
0
20
40
60
80
100
120
140
160
N M S
EDVI CKCS 
Age 
Level - - Level p value 
S N 0.0018* 
M N 0.2342 
S M 0.0109 
EDVI 
Level - Level p value 
S N 0,0369* 
M N 0,2330 
S M 1,0000 
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The analysis of variance of the variable La/Ao between the groups was studied 
using the Kruskal-Wallis test (Chi Q= 0,0472). The significance of difference 
between patient groups of the variable La/Ao was studied with the Wilcoxon 
test and resulted statistically different only between the N and the S group. No 
difference was found between the other groups. 
 
 
 
Chart 9 Box-plot of the La(Ao values distribution in the 3 CKCS subgroups. Data are presented as upper 
and lower quartiles and interquartile range (box), the median (horizontal line), and the maximum and 
minimum values (crosses). p-values for each couple are reported in the correspondent table (Wilcoxon 
test). 
 
The analysis of variance of the variable ESVI between the groups was studied 
using the Kruskal-Wallis test (Chi Q= 0,6974). Therefore the significance of 
difference of the mean between patient groups of the variable ESVI was studied 
with the Wilcoxon  test and no difference was found between the groups. 
 
The ANOVA of the variable EF% between the 3 groups was performed (F= 
0.3536). No statistically significant difference was found between the mean EF 
of the 3 groups using the Student’s t test. 
 
The ANOVA of the variable FS% between the 3 groups was performed 
(F=0.2471). No differences statistically significant were found between the mean 
FS% of the 3 groups with the Student’s t test. 
 
 
Proteomic analysis was performed in three different experimental groups as 
previously described. Two sera from normal dogs, two from mild affected and 
two from severely affected dogs were were analyzed through 2-D electrophoresis 
followed by MALDI TOF mass spectrometric analysis for protein identification. 
Among analyzed proteins three of them were found to be differentially 
expressed and were successfully identified through MS analysis. The first one, 
0,2
1,2
2,2
3,2
N M S
La/Ao CKCS 
La/Ao 
Level - Level p value 
S N 0,0369* 
S M 0,0512 
N M 0,8345 
58 
 
was found to be serum albumin and its expression was decreasing according to 
the severity of the pathology. The detail of the trend for serum albumin is shown 
in chart 11. Conversely it was found a strong up-regulation of some specific 
types of IgG and IgM according to the severity of the pathology. This trend is 
shown in chart 11, both the differential expression of those proteins were 
statistically significant with an anova p-value lower than 0,05. 
 
 
 
Chart 90: Representative 2-D maps of canine serum showing the differentially expressed proteins 
between experimental groups 
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6.1 Cirneco dell’Etna group 
 
Cirneco dell’Etna group: The Cirneco dell’Etna breed represented a small part of 
our population (4.6%). The prevalence of MVD among this breed was high 
(64%) and a statistical correlation between MVD and age was found: the age of 
the normal group was statistically different from the age of the other 3 groups. 
The oldest dogs were those affected by MVD, and all the dogs older than 6 years 
old  had echocardiographic signs of MVD. We expected that MVD, if present in 
the CdE breed, would have affect the oldest dogs, being a typical pathology of 
the elderly dogs. An unexpected result was the relatively young median age of 
the dogs affected by MVD: in particular the VS group had a mean age of 7 years. 
This result is unexpected, because MVD is defined as a pathology typical of the 
old, small breed dogs. The CdE breed is a medium size breed, and for its weight 
the old age is reached at 8 years old. Two of the dogs of the VS group were 
under the 8 years old and the other one was 8 years old. Therefore we can 
conclude that the CdE breed is predisposed to the development of MVD, and 
that the age of onset is relatively low. The membership of the CdE dogs to the 
Hunting cluster is maybe at the base of the predisposition of this breed to 
develop MVD. The CdE breed is a primitive hunting dog, that supposedly hasn’t 
been inbreed and manipulated by the human action like other breeds during the 
centuries. We can therefore imagine that if a common ancestor exists, MVD may 
have been introduced at a very early stage of breed development. The CdE have 
then inherited a set of mutations from that common source that have increased 
susceptibility to MVD, and may have reached a relatively high rates due to 
reductions in the gene pools of most breeds after development. 
 
The proteomic analysis of the CdE samples gave two important results: the 
alpha-1-antytripsina (A1AT) was up-regulated in the patients affected by MVD,  
according to the severity of the pathology, while the complement C3 was down-
regulated with the development of MVD, according to the stage of the disease. 
 
Alpha-1-antytripsina (A1AT): A1AT is a glycoprotein,  generally known as serum 
trypsin inhibitor. The protein was called "antitrypsin" because of its ability to 
covalently bind and irreversibly inactivate the enzyme trypsin in vitro. The term 
alpha-1 refers to the enzyme's behavior on protein electrophoresis. There are 
several "clusters" of proteins: albumin, alpha, beta and gamma 
(immunoglobulins). The non-albumin proteins are referred to as globulins. The 
alpha region can be further divided into two sub-regions, termed "1" and "2". 
Alpha 1-antitrypsin is the main enzyme of the alpha-globulin 1 region. The 
correct name, however, is alpha-1 proteinase inhibitor, because it is a serine 
protease inhibitor (serpin) inhibiting a wide variety of proteases. A1AT is an 
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acute-phase protein (APP). The APP are a class of proteins whose plasma 
concentrations increase (positive acute phase proteins) or decrease (negative 
acute phase proteins) in response to inflammation (acute-phase reaction also 
called acute phase response). APP have a wide range of activities that contribute 
to the host defence: they can directly neutralize inflammatory agents, help to 
minimize the extent of local tissue damage, as well as participate in tissue repair 
and regeneration. It protects tissues from enzymes of inflammatory cells, 
especially elastase, which normally digests damaged or aging cells and bacteria in 
order to provide for healing. There is a rapid increase in plasma concentration of 
many complement cascade components, the activation of which ultimately 
results in the local accumulation of neutrophils, macrophages and plasma 
proteins. Inflammation is essential for atherogenesis, and many inflammatory 
markers have been analyzed for their association with short- and long-term 
outcome in patients with manifestations of coronary artery disease and in 
apparently healthy subjects.  A1AT in human blood can increase to three or four 
times the normal level to protect tissues in times of infection, pregnancy, or 
other situations that subject the body to an increase in neutrophil elastase. In its 
absence, elastase is free to break down elastin , which contributes to the 
contractility of the lungs, resulting in respiratory complications such as 
emphysema leading to finally to COPD (chronic obstructive pulmonary disease). 
In the acute phase reaction, a further elevation is required to "limit" the damage 
caused by activated neutrophil granulocytes and their enzyme elastase, which 
breaks down the connective tissue fiber elastin. Because elastin is a major 
component of vessel wall elastic lamina, and degradation of elastic fibers may be 
important in the loss of vessel tone and the development of atherosclerosis, this 
implicates A1AT in the artherogenic process. The association between MVD 
and inflammation is not a novelty: in the last years there has been a growing 
interest in the role that inflammatory mediators may play in accelerating the 
pathology of MVD.  There is one report of elevated C-reactive protein 
concentrations in the serum of affected dogs, suggesting a possible role of low-
grade systemic inflammation in the disease progression. (Rush et al, 2006) 
Another study evaluating genomic expression patterns from the valves of dogs 
with MVD, confirmed activation of several pathways involved in cell signalling, 
inflammation, and extracellular matrix activation, with several inflammatory 
cytokines and serotonin-transforming growth factor identified as contributory to 
the development of the degenerative process in the valve. (Oyama and Chittur, 
2006). The up-regulation of the A1AT in the MVD patients may be related to 
the state of chronic inflammation of the affected valves. The damaged valves 
cells may activate the inflammatory cells. Subsequently, the A1AT could play a 
role as an opposer to the inflammatory agents, helping to minimize the local 
tissue damage, as well as participating in tissue repair and regeneration. Previous 
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works have demonstrated that inflammation plays an important role in the 
development of cardiovascular diseases: in patients with acute coronary 
syndrome, coronary atherosclerotic plaques are characterized by an abundant 
inflammatory infiltrate. (Correale ate al., 2012) 
 
Complement C3: The complement system is a group of proteins that made part 
of the immune system, and is the most important component of humoral 
autoimmunity in the natural defence mechanism. The complement proteins are 
activated by inflammation, infection and other pathogenetic mechanisms. The 
role of the complement is to protect the organism through the removal of the 
pathogens, or facilitating their control by other biological, serical or cellular 
mechanisms. The complement system is also involved in myocardial cell injury 
related to ischemia and reperfusion, and in the pathogenesis of atherosclerosis. 
Complement C3 (C3) is an acute phase reactant produced by the liver, secreted 
by activated macrophages at inflammation sites and by adipocytes, and has a 
central role in the immune system. C3 has been associated with atherosclerosis 
and cardiovascular risk factors in human medicine. Furthermore the fraction 
C4b of the complement has been associated recently to MVD: C4b resulted 
down-regulated in human MVD (Tan et al., 2013). The authors suggested that 
chronic infections and/or inflammation  could create immune complexes over a 
long period of time, resulting in a natural depletion of its components. The same 
process could explicate the C3 down-regulation of our patients. Moreover, the 
complement system is involved in myocardial cell injury and in the pathogenesis 
of atherosclerosis: it was demonstrated that many MVD hearts of dogs have 
histopathological lesions in the myocardium, including small foci of myocardial 
fibrosis and necrosis, as well as widespread intramural coronary arteriosclerosis. 
These chronic alterations could be a further mechanism of activation of the 
complement system, with final depletion of its components as the complement 
C3. 
 
6.2 Cavalier King Charles Spaniel group 
 
Cavalier King Charles Spaniel: The Cavalier King Charles Spaniel group 
represented a relatively modest part of our population (7%).  The prevalence of 
MVD among the CKCS breed was high (63%). The medium age of the total 
group was low (4 years). This result was expected, because the CKCS is the 
breed with the earliest onset of MVD, so that almost all the dogs included in the 
study were relatively young dogs. All the subjects mildly affected by MVD (M 
group) were young dogs: the mean age of this group was 4 years old, a very 
young age for a dog of that body weight. The S group had a mean age 
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statistically different from the two other groups (8.6 years), including the oldest 
subjects (6, 9 and 11 years old). This is an expected result, being the MVD a 
chronic and degenerative pathology, that in the CKCS has an early onset, and a 
chronic progression, so that the most severe cases are often seen in the oldest 
dogs. Even so, we have to notice that the mean age of the S group was still a 
young age if compared with the life expectancy of an healthy Cavalier King 
Charles Spaniel dog. This results confirm that the CKCS is a breed with a high 
predisposition to MVD, with a very early onset. 
The echocardiographic variables considered  were LVIDs, LVIDd, ESVI, 
EDVI, La/Ao ratio, FS% and EF%. The results obtained in the CKCS group 
reproduce the echocardiographic trend of MVD. The normal group had mean 
values in the range of normality. The M group presented values in the range of 
normality, but an increase in the mean values was found. The ESVI and La/Ao 
were next to the border line values of normality. 
The echocardiographic values of the S group were above the normal limits, in 
particular EDVI and La/Ao ratio were severely increased, and the mean La/Ao 
ratio was markedly increased, underling the poor prognosis of the S group dogs. 
A statistic significant difference of the mean values was found only between N 
and S group, for the EDVI and La/Ao ratio variables, because of the normal 
values of the mildly affected dogs, confirming the substantial overlap of the 
numeric variables of a normal dog with a dog in the first stage of MVD 
These results were those expected, because MVD is a chronic pathology with a 
constant but often slow progression, so that the mildly affected dogs had 
echocardiographic values in the range of normality, but with an increasing trend 
if compared with the normal dogs, while the severely affected dogs had values 
openly above the normal range. The variables considered were those indicative 
of left ventricular function and left atrial dilation, so that an increase in these 
variables above the normal range indicates the presence of morphologic and 
hemodynamic alterations secondary to mitral valve regurgitation, and the passage 
from ACVIM stage b1 to the ACVIM stages b2,c and d. This results confirm the 
fact that in the first stages of the pathology no morphologic or hemodynamic 
alteration are found. For the mildly affected dogs the echocardiographic aspect 
of the mitral valve apparatus and the Doppler study of the mitral flow will be 
pivotal to assess the presence/absence of MVD, while for the severely affected 
dogs the evaluation of the above mentioned variables is mandatory to assess the 
global heart status.  
The proteomic analysis on the CKCS samples emphasized some important 
differences among the groups: the serum albumin was down-regulated in our 
samples, according to the severity of the pathology, while it was found a strong 
up-regulation of some specific types of IgG and IgM, according to the severity 
of the pathology. The proteomics results of the two breeds were markedly 
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different to each other. We made some hypothesis about this discrepancy, and it 
was thought that the CdE samples resulted different, with a worst quality of 
proteomic analysis results, because they were hemolytic, so that the haemoglobin 
present in the sera may have affected the proteomic analysis, covering some 
protein expression. With the CKCS dogs the blood samples were taken with all 
the possible precautions to avoid the hemolysis, and the sera obtained were of 
better quality than that of the CdE group. This is a possible explication to the 
different proteomics results obtained. Anyway, we have to remember that the 
samples were taken from totally different breeds, and the genetic component of 
the protein expression may have play an important role. 
 
Serum albumin: The albumins are a family of globular proteins, the most 
common of which is serum albumin. The albumin family consists of all proteins 
that are water-soluble, are moderately soluble in concentrated salt solutions, and 
experience heat denaturation. Albumins are commonly found in blood plasma, 
and are unique from other blood proteins in that they are not glycosylated. 
Albumin is the main protein of the blood plasma. It binds water, cations (such as 
Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine and 
pharmaceuticals. Its main function is to regulate the colloidal osmotic pressure 
of blood.  Serum albumin is the most abundant blood plasma protein and is 
produced in the liver and forms a large proportion of all plasma proteins. Serum 
albumins are important in regulating blood volume by maintaining the oncotic 
pressure (also known as colloid osmotic pressure) of the blood compartment. 
They also serve as carriers for molecules of low water solubility isolating their 
hydrophobic nature, including lipid soluble hormones, bile salts, unconjugated 
bilirubin, free fatty acids (apoprotein), calcium, ions (transferrin), and some 
drugs.  Low albumin (hypoalbuminemia) concentration may be caused by liver 
disease, nephrotic syndrome, burns, protein-losing enteropathy, malabsorption, 
malnutrition, late pregnancy, artefact, genetic variations and malignancy. Several 
processes control plasma albumin concentration, including the absolute rate of 
albumin synthesis, the fractional catabolic rate, albumin distribution between the 
vascular and extravascular compartments, and exogenous loss of albumin. The 
rate of albumin synthesis is affected by both nutrition and inflammation, given 
that albumin is a negative acute phase protein. 
The observation that serum albumin is a negative acute phase protein supports 
the contention that serum albumin concentration is a marker of inflammation. 
(Don & Kaysen, 2004) We can therefore suppose that, similar to the A1AT and 
to the complement C3, the decrease in serum albumin concentration in our 
MVD patients may be a consequence of the state of chronic inflammation that 
could play an important role in the myxomatous pathogenesis. 
Hypoalbuminemia in human patients suffering from CHF is common and it is 
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considered a strong predictor of death in patients with CHF. Hypoalbuminemia 
in these patients is not due only to malnutrition, loss of appetite in the chronic 
patient and to cardiac cachexia. In these patients hypoalbuminemia is caused by 
chronic inflammation,  liver dysfunction from right ventricular failure, hyper 
catabolism and hemodiluition. (Yamamoto et al., 2012) In our patients the 
decrease in the serum albumin level is evident above all in the S group (chart 11), 
that was the group composed by the severely affected dogs with congestive heart 
failure as a consequence of MVD. For this reason we can suppose that the above 
mentioned mechanisms that are demonstrated in human medicine, could be 
established in the canine patient, being the pathogenesis of MVD common to 
the two species. 
 
IgG and IgM:  Immunoglobulins are glycoprotein molecules that are produced by 
plasma cells in response to an immunogen and which function as antibodies. 
The immunoglobulins derive their name from the finding that they migrate with 
globular proteins when antibody-containing serum is placed in an electrical field  
Immunoglobulin G (IgG) and immunoglobulin M (IgM) are two antibodies 
isotypes. Antibodies are major components of the immune system. IgG is the 
main antibody isotype found in blood and extracellular fluid allowing it to 
control infection of body tissues. By binding many kinds of pathogens, IgG 
protects the body from infection. IgM antibodies appear early in the course of an 
infection and usually reappear, to a lesser extent, after further exposure. 
Immunoglobulins bind specifically to one or a few closely related antigens. Each 
immunoglobulin actually binds to a specific antigenic determinant. Antigen 
binding by antibodies is the primary function of antibodies and can result in 
protection of the host.  Frequently the binding of an antibody to an antigen has 
no direct biological effect. Rather, the significant biological effects are a 
consequence of secondary "effector functions" of the antibodies. The 
immunoglobulins mediate a variety of these effector functions. Such effector 
functions include fixation of complement and binding to various cell types.  
To the author knowledge, no association between IgG, IgM and canine MVD 
has been made before. Conversely, in human medicine, an increased prevalence 
of MVD is reported in patients with systemic lupus erythematosus and 
autoimmune thyroid disease. In 2009 Evangelopoulos et al. examined serum 
samples from humans MVD subjects for various organ and non-organ specific 
autoantibodies. IgA and IgG were found at a statistically significant higher 
incidence in the MVD affected humans, insinuating the presence of subclinical 
autoimmunity and autoimmune mechanisms involved in the MVD pathogenesis. 
We can suppose that, playing a role in the complement, the up-regulation of IgG 
and IgM in our samples could be related, once again, to the state of chronic 
inflammation of the MVD patients. Furthermore, the MVD patients are more 
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prone to develop infective endocarditis, a condition that determines a great 
stimulation of the immune system and an up-regulation of the antibodies.  
  
68 
 
  
69 
 
 
 
 
 
CHAPTER 7 
 
 
 
 
 
Limitations of the study 
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7.1 Limitations of the study 
 
The present study has been conducted on a relatively small number of cases. In 
particular, the severe groups in both the CdE and the CKCS were composed of 
a fairy small number of dogs. It was not possible to have five dogs of each 
category because just two dogs in the severe stage were recruited for the CdE 
group and just three dogs in the CKCS group, being the dogs with the highest 
mortality rate.  This is a great limitation for all the statistical analysis. 
For the future it could be of great interest to increase the number of dogs 
included in the study, enhancing the statistical powerful 
 
The clinical part of the present study didn’t required any economic effort, being 
a prospective study made on our pool of patients, but all the proteomic 
procedures are relatively high cost techniques, requiring expensive materials and 
a proteomic laboratory with prepared and trained team. 
. 
In the present study we didn’t consider the anatomic alterations of the valves 
because we didn’t perform any post-mortem examination on our patients. For 
this reason we didn’t compare the autoptical findings with the clinical and 
proteomic results. For the future it could be interesting to evaluate the 
proteomic alterations in both mitral valve tissue and sera, comparing the findings 
with the clinical features.  
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8.1 Conclusions 
 
Based on our study results, we can conclude that the Cirneco dell’Etna breed is a 
primitive hunting breed predisposed to the development of MVD, with an early 
onset of the pathology. All the CdE dogs older than 6 years should be therefore 
evaluated for MVD, and included in a screening program. To the author’s 
knowledge the CdE breed was never included before among the breeds 
predisposed to MVD. The membership of the CdE dogs to the Hunting cluster 
is maybe at the base of the high prevalence of MVD among the breed. For the 
future it will be of great interest to continue the genetic studies conducted on the 
breeds clusters, including the CdE in the Hunting cluster. 
 
We confirmed that Cavalier King Charles Spaniel is a breed with a high 
prevalence of MVD and an early onset too, as previously reported. In our study 
we observed that the disease is chronic, with a slow progression. In the first 
stages of the pathology no morphologic or hemodynamic alteration are found 
and the echocardiographic diagnosis is based on the mitral valve apparatus 
aspect and on the Doppler identification of the regurgitation: in these dogs the 
echocardiographic aspect of the mitral valve apparatus and the Doppler study of 
the mitral flow will be pivotal to assess the presence/absence of MVD, even if a 
complete echocardiographic exam should be always performed. Conversely, in 
the advanced stage the echocardiographic variables indicative of systolic 
function, ventricular overload, atrial dilation and left ventricular function are 
markedly different from the normal values, and the echocardiographic diagnosis 
is completed with the evaluation of the altered hemodynamic status and of the 
morphologic abnormalities.  
 
The proteomic analysis conducted on our samples and correlated to the clinical 
results, indicate that the MVD is a pathology that is strictly connected to a 
chronic low inflammation state. The up-regulation of A1AT, IgG, IgM, and the 
down-regulation of complement C3 and serum albumin are connected with an 
inflammatory status, that cause a depletion of the components of the 
complement system, an activation of the acute phase proteins and of the 
components of immunity response like IgG and IgM immunoglobulins.  
 
The hypothesis that MVD could be related to a chronic inflammation was 
already speculated in the last years, and, based on the present study results, we 
think that the analysis of the inflammatory mediators in MVD patients could be 
a great chance to uncover the pathogenetic mechanism at the base of mitral 
valve disease. 
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